Financial Performance - The company reported total revenue of RMB 1,399,808,311.93 for Q1 2024, a decrease of 37.76% compared to RMB 2,249,034,497.62 in the same period last year[10]. - Net profit attributable to shareholders was RMB 281,970,252.06, down 55.27% from RMB 630,346,004.43 year-on-year[10]. - The net profit after deducting non-recurring items was RMB 253,974,228.11, reflecting a 58.88% decline compared to RMB 617,637,901.61 in the previous year[10]. - Basic and diluted earnings per share were both RMB 0.76, down 55.81% from RMB 1.72 in the same period last year[10]. - Total revenue for Q1 2024 was approximately ¥1.40 billion, a decrease of 37.76% compared to ¥2.25 billion in Q1 2023, primarily due to the impact of large orders in the same period last year[18]. - Operating profit decreased to RMB 294.69 million, a decline of 58.5% compared to RMB 709.95 million in the prior period[38]. - Net profit for the reporting period was RMB 279.53 million, down 55.5% from RMB 627.89 million in the previous period[40]. - Total revenue for the reporting period was RMB 1.40 billion, down 37.8% from RMB 2.25 billion in the previous period[38]. - The company reported a net loss attributable to the parent company of RMB 281,971,000 in Q1 2024, compared to a profit of RMB 630,346,000 in Q1 2023[47]. Revenue Breakdown - Revenue from small molecule business reached RMB 1,223,000,000, with a year-on-year growth of 26.58% after excluding last year's large order impact[13]. - Revenue from emerging businesses was RMB 176,000,000, down 29.30% year-on-year due to the ongoing impact of the domestic investment environment[13]. - Cash received from sales of goods and services was approximately ¥1.74 billion, down 36.76% from ¥2.76 billion in the previous year, influenced by large order repayments from last year[18]. Costs and Expenses - Total costs for Q1 2024 were approximately ¥1.14 billion, down 27.27% from ¥1.57 billion in Q1 2023, mainly due to the decline in revenue[18]. - Sales expenses increased by 31.95% to approximately ¥44.62 million, reflecting continued investment in market expansion and sales activities[18]. - The company reported a significant increase in tax and additional charges, which rose by 374.77% to approximately ¥41 million, attributed to export tax rebates[18]. - Research and development expenses for the period were RMB 169.44 million, an increase from RMB 162.10 million in the previous period[38]. - Research and development expenses for Q1 2024 were RMB 169,442,000, slightly higher than RMB 162,097,000 in Q1 2023[47]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 19,841,423,232.54, a slight increase of 0.38% from RMB 19,767,158,652.70 at the end of the previous year[10]. - Total current assets decreased to RMB 12.11 billion from RMB 12.35 billion, primarily due to a reduction in trading financial assets[31]. - The company reported a total liability of RMB 2.23 billion, slightly down from RMB 2.26 billion at the beginning of the period[35]. - The company’s total equity as of March 31, 2024, was RMB 17,606,958,000, an increase from RMB 17,509,979,000 at the end of the previous year[55]. Cash Flow and Investments - Net cash flow from operating activities for the reporting period was RMB 490,666,474.36, significantly lower than RMB 1,303,525,263.66 in the previous period[44]. - Cash and cash equivalents at the end of Q1 2024 totaled RMB 4,774,669,819.21, down from RMB 5,379,198,112.41 at the end of the previous year[45]. - The cash flow from investing activities showed a net outflow of RMB 284,603,126.59, compared to a net outflow of RMB 327,218,213.85 in the previous period[44]. - The company experienced a foreign exchange gain of RMB 15,685,123.62 during the reporting period, contrasting with a loss of RMB 15,286,791.15 in the previous period[45]. - The company experienced a net cash outflow from investing activities of RMB 284,603 thousand in Q1 2024, compared to RMB 327,218 thousand in Q1 2023[59]. Share Repurchase and Capital Management - The company repurchased shares, resulting in cash payments of approximately ¥218.69 million, marking a new strategy in capital management[18]. - The company plans to repurchase shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price not exceeding RMB 157 per share[29]. - The financing activities resulted in a net cash outflow of RMB 218,690 thousand in Q1 2024, with share repurchase payments amounting to RMB 213,367 thousand[59]. Project Development - The company confirmed 30 small molecule commercialization projects and 148 clinical stage projects, including 41 in Phase III[13].

证券代码：002821 证券简称：凯莱英 公告编号：2024-038 凯莱英医药集团（天津）股份有限公司 关于回购公司股份比例达到 2%暨回购进展的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大会，审议通过了《关于回购公司股份方案的议案》， 根据股份回购方案，公司将采用集中竞价交易的方式从二级市场回购公司 A 股 股份，本次回购股份的资金总额将不低于人民币 60,000 万元（含），且不超过人 民币 120,000 万元（含）；回购价格不超过 157 元/股。具体内容详见刊登在《证 券时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 规定： （一）公司未在下列期间回购股份： 1、自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 2、中国证监会和深圳证券交 ...

Financial Performance - Total revenue for Q1 2024 was RMB 1.40 billion, a decrease of 37.76% compared to RMB 2.25 billion in the same period last year[6] - Net profit attributable to shareholders was RMB 281.97 million, down 55.27% from RMB 630.35 million year-on-year[6] - Basic and diluted earnings per share were both RMB 0.76, a decrease of 55.81% compared to RMB 1.72 in the previous year[6] - In Q1 2024, the company's net profit was approximately ¥279.53 million, a decrease of 55.5% compared to ¥627.89 million in the same period last year[24] - Operating profit for Q1 2024 was approximately ¥294.69 million, compared to ¥709.95 million in Q1 2023, reflecting a decline of 58.5%[24] - The company reported a total comprehensive income of approximately ¥279.82 million in Q1 2024, compared to ¥622.76 million in Q1 2023[24] Revenue Breakdown - Revenue from small molecule business reached RMB 1.22 billion, with a year-on-year growth of 26.58% after excluding the impact of large orders from the previous year[8] - Revenue from emerging businesses was RMB 176 million, a decline of 29.30% year-on-year due to the ongoing impact of the domestic investment and financing environment[8] - Total operating revenue for the first quarter was CNY 1,399,808,311.93, a decrease of 37.8% compared to CNY 2,249,034,497.62 in the previous period[23] Cash Flow and Liquidity - Cash flow from operating activities was RMB 490.67 million, down 62.36% from RMB 1.30 billion in the same period last year[6] - Total cash and cash equivalents at the end of Q1 2024 were approximately ¥4.77 billion, down from ¥5.38 billion at the end of Q1 2023[26] - The company received cash from operating activities totaling approximately ¥1.87 billion in Q1 2024, down from ¥2.86 billion in the previous year[25] - Cash flow from investing activities in Q1 2024 was negative at approximately -¥284.60 million, compared to -¥327.22 million in Q1 2023[26] Assets and Liabilities - The total assets at the end of the reporting period were RMB 19.84 billion, a slight increase of 0.38% from RMB 19.77 billion at the end of the previous year[6] - Total liabilities decreased to CNY 2,234,464,626.88 from CNY 2,257,179,887.55, indicating a reduction in financial obligations[22] - The company’s equity attributable to shareholders rose to CNY 17,578,908,929.36 from CNY 17,479,716,341.34, reflecting growth in shareholder value[22] Shareholder Information - The top 10 shareholders hold significant stakes, with ASYMCHEM LABORATORIES owning 31.16% and HKSCC NOMINEES LIMITED holding 7.46% of the shares[15] - The company reported a total of 115,133,168 shares held by ASYMCHEM LABORATORIES, representing the largest single shareholder[15] - The company has a total of 6,555,504 shares held by Tianjin Guorong Business Consulting Co., Ltd., which is involved in margin trading[16] - The company has established a stock repurchase plan approved in the recent shareholder meetings, indicating a commitment to enhancing shareholder value[18] Strategic Initiatives - The company is accelerating its overseas capacity layout and enhancing operational management systems to improve overall profitability[7] - The report indicates that the company is actively engaging in market expansion and strategic initiatives, including potential mergers and acquisitions[18] - The company plans to repurchase A-shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price capped at RMB 157 per share[18] - The company plans to expand its market presence and invest in new product development to drive future growth[21] Research and Development - The report highlights the company's ongoing research and development efforts in new products and technologies, although specific details were not disclosed[18] - Research and development expenses were CNY 169,442,435.66, slightly up from CNY 162,096,744.48, indicating continued investment in innovation[23]

Financial Performance - In 2023, Asymchem Laboratories achieved a total revenue growth of 23.67% year-on-year, excluding the impact of large orders[7]. - The company's revenue for the year ended December 31, 2023, was approximately RMB 7,781,436 thousand, a decrease of 23.94% compared to RMB 10,230,186 thousand for the year ended December 31, 2022[18]. - Gross profit for the reporting period was approximately RMB 3,959,636 thousand, down 18.06% from RMB 4,832,588 thousand in the previous year[18]. - Net profit attributable to shareholders for the reporting period was approximately RMB 2,268,811 thousand, a decline of 31.28% from RMB 3,301,635 thousand in the prior year[18]. - The gross margin for the reporting period improved to 50.89%, compared to 47.24% in the previous year[19]. - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, a decrease of 23.23% compared to 2022[80]. - The company reported a significant increase in revenue, achieving a total of $1.2 billion for the fiscal year, representing a 15% year-over-year growth[165]. - The company reported a 5% increase in gross margin, reaching 45% for the fiscal year[165]. Business Growth and Development - Revenue from small molecule CDMO business grew by 75.56% year-on-year, indicating strong collaboration with multinational pharmaceutical companies[7]. - The company celebrated its 25th anniversary in 2023, marking significant commercial breakthroughs and major orders in the small molecule CDMO sector[7]. - The company has increased its production capacity in China, including commercial production capabilities for peptides and ADCs, to meet the demands of emerging businesses[13]. - The company reported a significant increase in employee count from 3,840 at the end of 2019 to 9,788 currently, reflecting its growth trajectory[16]. - The company aims to expand its global presence and is optimistic about the recovery of domestic markets and the growth of emerging businesses[13]. - The company aims to enhance operational efficiency and reduce costs while expanding its market presence in Europe and Japan[24]. - The company aims to diversify its multinational pharmaceutical client base and has made significant breakthroughs in the Japanese market after years of penetration[36]. - The company has established long-term partnerships with 16 out of the top 20 global pharmaceutical companies, demonstrating strong customer loyalty[132]. Research and Development - Continuous production technology and synthetic biology technology have been developed into comprehensive platforms for external technology output, enhancing efficiency and reducing costs[9]. - The company is prioritizing the advancement of its R&D platform to maintain its leading technological position in the industry[9]. - R&D expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue, with plans for continued investment in R&D[61]. - The establishment of the biopharmaceutical technology center (CBTI) in Shanghai aims to enhance R&D capabilities and improve process development[56]. - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[60]. - The company is committed to continuous R&D investment to strengthen its technology-driven approach and maintain its competitive edge in the CDMO sector[137]. Market Trends and Challenges - The global innovation drug development landscape faced challenges in 2023, impacting the entire CXO industry[6]. - Asymchem's strategic deployment has strengthened its capabilities despite the pressures from market uncertainties[6]. - The company is currently conducting 356 clinical research projects, with 123 in Phase II or later[53]. - The company faces potential risks including major innovative drug recalls, operational challenges in clinical projects, and core technical personnel turnover[149]. Operational Efficiency and Cost Management - The company aims to maximize the utilization of newly added production capacity while minimizing raw material waste and reducing operating costs[72]. - Sales costs for 2023 were RMB 3,821.80 million, a decrease of 29.19% compared to RMB 5,397.60 million in 2022, attributed to improved gross margins and strict cost control measures[84]. - The overall gross margin increased by 3.65% to 50.92% in 2023, driven by a higher gross margin from commercial projects and effective cost management[86]. - The company emphasizes optimizing profitability by improving the gross margin of its small molecule CDMO business and controlling production costs through efficiency and management[145]. Strategic Initiatives - The company is actively seeking investments to enrich its service offerings and expand its overseas presence, focusing on commercial production for multinational companies[141]. - The company plans to enhance its delivery capabilities and expand overseas markets by strengthening management and operational systems[146]. - The company aims to deepen relationships with existing clients while expanding its global customer base, particularly targeting small and medium-sized innovative pharmaceutical companies[139]. - The company is focused on diversifying into new drug categories and service types, including biopharmaceutical CDMO services and clinical research[140]. Corporate Governance and Management - The management team has an average of over 20 years of experience in their respective fields, contributing to stable governance and strategic direction[136]. - Zhang Da serves as the Chief Financial Officer and Chief Operating Officer, responsible for financial operations and investment activities[153]. - The supervisory board consists of three members, including two shareholder representatives and one employee representative[162]. Dividend and Shareholder Information - The company plans to distribute a final dividend of RMB 1.80 per share, totaling approximately RMB 664,080,355.80, subject to shareholder approval[18]. - The board proposed a profit distribution plan for 2023, recommending a dividend of RMB 18.00 per 10 shares of common stock, totaling approximately RMB 664,080,355.80 (including tax) based on 369,471,533 shares issued[186]. - The proposed profit distribution plan for 2023 is subject to approval at the annual general meeting of shareholders and is expected to be paid within two months after the meeting[186].

证券代码：002821 证券简称：凯莱英 公告编号：2024-036 凯莱英医药集团（天津）股份有限公司 关于举办 2023 年度网上业绩说明会的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 3 月 29 日披露了 2023 年年度报告全文及摘要，相关内容详见巨潮资讯网 （http://www.cninfo.com.cn）。为便于投资者能够进一步了解公司 2023 年度 的经营情况，公司定于 2024 年 4 月 22 日（星期一）15:00-16:00 在全景网举办 2023 年度业绩说明会（以下简称"本次年度业绩说明会"）。本次年度业绩说明 会将采用网络远程的方式举行，公司通过文字直播方式回复投资者提问，投资者 可登录全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度业 绩说明会。 出席本次说明会的人员有：公司董事长、首席执行官 HAO HONG，执行董事、 首席运营官、首席财务官张达，高级副总裁兼董事会秘书徐向科，独立非执行董 事孙雪娇（具体参会人员 ...

证券代码：002821 证券简称：凯莱英 公告编号：2024-035 凯莱英医药集团（天津）股份有限公司 关于回购公司股份比例达到 1%暨回购进展的公告 一、回购公司股份的进展公告 截至 2024 年 4 月 10 日，公司累计通过回购专用证券账户以集中竞价交易方 式回购公司股份数量为 3,429,389 股，占公司 A 股总股本的 1.0030%，最高成交 价为 102.00 元/股，最低成交价为 80.90 元/股，成交总金额为 309,767,047.92 元（不含交易费用）。本次回购股份符合公司回购方案及相关法律法规要求。 二、其他说明 公司回购股份的时间、回购股份的数量及集中竞价交易的委托时段符合《深 圳证券交易所上市公司自律监管指引第 9 号——回购股份（2023 年修订）》相关 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大会，审议通过了《关于回购公司股 ...

[Table_MainInfo] 公司研究/医药与健康护理/化学制药 证券研究报告 凯莱英（002821）公司年报点评 2024年04月08日 [Table_InvestInfo] 凯莱英 2023 年报点评：收入端稳健增长， 投资评级 优于大市 维持 新兴业务趋势向好，看好公司长期发展 股票数据 0[4T月ab0le8_日S收to盘ck价（In元fo）] 80.86 [Table_Summary] 52周股价波动（元） 80.71-165.27 投资要点： 总股本/流通A股（百万股） 369/329 总市值/流通市值（百万元） 29875/28800 相关研究  公告：凯莱英发布2023年报。 [《T（a更bl新e_）R小ep分o子rt业In务fo稳] 健增长，新兴业务板  点评： 块快速增长，看好公司长期稳健发展》 2023.04.10  收入端保持高速增长态势。2023年，公司营业收入78.25亿元，剔除大订单 《公司营收持续高速增长，建议关注电生理行 后收入 54.05 亿元，同比增长 24.37%。归母净利润 22.69 亿元，同比下降 业集采》2023.04.10 31.28%；扣非归母净利 ...

1、本次解除 2020 年限制性股票激励计划首次授予部分第三次解除限售的限 售股票数量为 373,170 股，占公司 A 股总股本 0.11%，涉及股东人数 194 人； 2、本次解除限售的股权激励股份上市流通日期为：2024 年 4 月 11 日。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于2024年3月15 日召开第四届董事会第四十七次会议审议通过了《关于2020年限制性股票激励计 划首次授予部分第三个解除限售期解除限售条件成就的议案》。公司董事会认为 公司2020年限制性股票激励计划首次授予部分的第三个解除限售期已符合解除限 售条件。 2020 年限制性股票激励计划首次授予部分 第三次解除限售上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据公司 2020 年第三次临时股东大会审议授权及公司 2020 年限制性股票激 励计划相关规定，公司办理了 2020 年限制性股票激励计划首次授予部分第三次解 除限售上市流通手续，现就有关事项说明如下： 一、股权激励计划已履行的相关审批程序简述 证券代码：002821 ...

证券研究报告 公司点评 凯莱英(002821.SZ) 医药生物｜ 医疗服务 常规业务增长较快，商业化订单储备充足 2024年04月01日 预测指标 2022A 2023A 2024E 2025E 2026E 评级 买入 主营收入（亿元） 102.55 78.25 64.62 79.11 97.88 归母净利润（亿元） 33.02 22.69 12.15 15.18 19.06 评级变动 维持 每股收益（元） 8.94 6.14 3.29 4.11 5.16 交易数据 每股净资产（元） 42.35 47.31 50.13 53.65 58.07 当前价格（元） 86.04 P/E 9.63 14.01 26.16 20.94 16.68 52周价格区间（元） 84.05-164.00 P/B 2.03 1.82 1.72 1.60 1.48 总市值（百万） 30954.83 资料来源：Wind，财信证券 流通市值（百万） 28242.20 总股本（万股） 36947.20 投资要点： 流通股（万股） 35579.90  事件：公司发布 2023年年度报告。 涨跌幅比较  剔除大订单后的常规业务增长迅速，国外 ...

公 司 研 证券研究报告 究 ＃industryId＃ 医药生物 ＃investSuggestion＃ ＃ ＃dyC凯om莱pan英y＃ （002821.SZ ） investSug 增持 ( 维ges持tionC）h 000009 ＃title＃ 大订单交付顺利，各项业务保持向好趋势 ange＃ ＃createTime1＃ 2024年4 月 8日 投资要点 公 ＃市场ma数rk据etData＃ ＃summary＃  近日，凯莱英发布了2023年年报。2023年公司实现营业收入78.25亿元， 司 日期 2024-04-03 同比下降23.70%；实现归母净利润22.69亿元，同比下降31.28%；实现 点 收盘价（元） 85.09 扣非归母净利润21.04亿元，同比下降34.87%；实现经营现金流净额35.5 评 总股本（百万股） 369.47 亿元，同比增长8.00%。 报 流通股本（百万股） 328.24 告 净资产（百万元） 17479.72  点评：2023年，境内外生物医药融资环境持续低迷，公司顺利实现大订 总资产（百万元） 单交付后，剔除大订单业务实现稳健增长。其中，小分子商业化项目收 19 ...